JAK1 and colorectal carcinoma: For four CRC cell lines, we validated the kinome results by western blots, wherein combination treatment showed marked reductions in phosphorylation of JAK1/2/3 and STAT3 (targets for JAK/HDACi) and pEGFR and pERK1/2 kinases (targets for regorafenib) (Fig. 3D).